BofA is moving to No Rating on Inari Medical (NARI) after Stryker agreed to acquire Inari for $4.9B, or $80 in cash per share. Given the deal announcement, the firm believes that the stock is no longer trading on fundamentals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Inari Medical downgraded to Market Perform from Outperform at William Blair
- Inari Medical price target raised at Piper after agreeing to be acquired
- Inari Medical downgraded to Hold from Buy at Canaccord
- Inari Medical downgraded to Hold from Buy at Deutsche Bank
- Inari Medical downgraded to Neutral from Outperform at Baird